![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
The patent claims that trifunctional (TrFAb) and trispecific antibodies (TrSAb) will redirect immune effectors to tumor associated antigens (TAAs) while downregulating allo-activation of donor T cells, leading to reduced graft- versus-host disease (GvHD). A TrFAb is a bispecific antibody (BiAb) that binds to immune effector cells and targets a TAA, whilst binding of the Fc-portion of the TrFAb to Fcγ receptors (FcγR) on immune effector cells leads to downregulation of allo-activation of donor T cells responsible for mediating GvHD. Furthermore, a TrSAb consists of a proposed construct that binds to immune effectors and to two separate TAAs while the Fc-portion of the TrSAb constructs interacts to downregulate allo-activation as proposed in the TrFAb construct. The patent claims that infusion of TrFAb or TrSAb would markedly improve antitumor activity whilst maintaining potent anti-GvHD activity when used after allogeneic stem cell transplantation for both hematologic malignancies and solid tumors.
Acknowledgements
LG Lum is supported in part by a R01 grant CA 92344 from the National Cancer Institute, a Translational Grant # 60660-5 from the Leukemia & Lymphoma Society, a grant from the Michigan Cell Therapy for Excellence Grant # 1819 and funds from the Barbara Ann Karmanos Cancer Institute.
Patent Details
Title Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for graft-versus-host disease in allogeneic antitumor cell therapy.
Assignee Trion Pharma GmbH.
Inventors Lindhofer H, Slavin S, Morecki S.
Priority date 30/11/04.
Filing date 30/11/04.
Publication date 01/06/06.
Publication no. US200060115481.